Vyome Holdings, IncHIND
Price (close)
$2.06
Market cap
$14.5M
P/E
—
Revenue (TTM)
$129,724
Net income
-$11.3M
Dividend yield
—
1-year total return
-61.9%
Net margin
-8716.8%
Revenue growth
-67.1%
Debt / equity
—
What Vyome Holdings, Inc does.
Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the “Company”) completed the merger pursuant to the Agreement and Plan
of Merger, dated as of July 8, 2024, as amended (the “Merger Agreement”), by and among the Company, Raider Lifesciences Inc.,
Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the “Merger”).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.3M | $13.6M | $11.2M | $8.7M | $256,944 | $319,714 |
| Net income | -$21.6M | -$63.1M | -$46.2M | -$11.4M | -$1.4M | -$10.3M |
| Free cash flow | -$8.7M | -$15.7M | -$22.0M | -$17.0M | — | — |
More on HIND.
- Vyome Holdings, Inc summary
- Vyome Holdings, Inc financial statements
- Vyome Holdings, Inc key metrics
- Vyome Holdings, Inc health scores and style box
- Vyome Holdings, Inc earnings
- Vyome Holdings, Inc dividends
- Vyome Holdings, Inc valuation
- Vyome Holdings, Inc ownership and insiders
- Vyome Holdings, Inc peers
Figures from Vyome Holdings, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.